ecteinascidin 743 has been researched along with ifosfamide in 26 studies
| Studies (ecteinascidin 743) | Trials (ecteinascidin 743) | Recent Studies (post-2010) (ecteinascidin 743) | Studies (ifosfamide) | Trials (ifosfamide) | Recent Studies (post-2010) (ifosfamide) |
|---|---|---|---|---|---|
| 660 | 102 | 404 | 5,045 | 1,430 | 1,113 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 19 (73.08) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Biron, P; Blay, JY; Ray-Coquard, I | 1 |
| Daniels, S; McTiernan, A; Roylance, R; Seddon, B; Sykes, K; Whelan, J | 1 |
| Thornton, K | 1 |
| Baker, LH; Blay, JY; Chawla, SP; Demetri, GD; Elsayed, YA; Gómez, J; Hande, KR; Izquierdo, MA; Keohan, ML; Le Cesne, A; Lebedinsky, C; Park, YC; Ritch, P; Samuels, BL; Schuetze, S; von Mehren, M | 1 |
| Croué, A; Pavageau, AH; Reguerre, Y; Rialland, X; Rousselet, MC | 1 |
| Bui-Nguyen, B; Italiano, A; Toulmonde, M | 1 |
| Contreras Ibáñez, JA; Díaz Gómez, L; Navas García, N | 1 |
| Al-Muderis, O; Constantinidou, A; Fisher, C; Jones, RL; Judson, IR; Olmos, D; Scurr, M; Thway, K | 1 |
| Movva, S; Verschraegen, C | 1 |
| Alfaro, V; Blay, JY; Chawla, SP; Hendifar, A; Hohenberger, P; Lardelli, P; Leahy, MG; Nguyen, BB; Nieto, A; Patel, SR; Penel, N; Piperno-Neumann, S; Santoro, A; Staddon, AP | 1 |
| Cornillie, J; Hompes, D; Li, H; Schöffski, P; Wozniak, A | 1 |
| Basso, U; Maruzzo, M; Montesco, MC; Rastrelli, M; Roma, A; Zanardi, E | 1 |
| Grignani, G; Martín-Broto, J; Reichardt, P; Schuler, M | 1 |
| De Sanctis, R; Marrari, A; Santoro, A | 1 |
| Baresic, T; Buonadonna, A; Canzonieri, V; Corona, G; Lara, DP; Miolo, G; Santeufemia, DA; Viel, A | 1 |
| Badalamenti, G; Bello, E; Casali, PG; Collini, P; Colombo, C; Cominetti, D; D'Incalci, M; Dagrada, GP; Dei Tos, AP; Frapolli, R; Gronchi, A; Morosi, C; Negri, T; Pilotti, S; Provenzano, S; Renne, SL; Saponara, M; Stacchiotti, S; Tortoreto, M; Vincenzi, B; Zaffaroni, N; Zuco, V | 1 |
| Armento, G; Badalamenti, G; Catania, G; Incorvaia, L; Maltese, G; Napolitano, A; Santini, D; Silletta, M; Spalato Ceruso, M; Tonini, G; Valeri, S; Vincenzi, B | 1 |
| Desar, IME; Fleuren, EDG; van der Graaf, WTA | 1 |
| Cornillie, J; Debiec-Rychter, M; Hompes, D; Langmans, C; Schöffski, P; Sciot, R; van Cann, T; Vandenbempt, I; Wozniak, A | 1 |
| Jones, RL | 1 |
| Blay, JY | 1 |
| Hindi, N; Martin-Broto, J; Moura, DS | 1 |
| Caldari, E; De Paolis, M; Fiore, M; Giannini, C; Pirini, MG; Sambri, A; Spinnato, P; Zucchini, R | 1 |
| Schöffski, P | 1 |
9 review(s) available for ecteinascidin 743 and ifosfamide
| Article | Year |
|---|---|
[High-dose chemotherapy in soft tissue sarcomas of adults].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Dioxoles; Dose-Response Relationship, Drug; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Isoquinolines; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2001 |
Chemotherapeutic management of soft tissue sarcoma.
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dioxoles; Doxorubicin; Humans; Ifosfamide; Neoadjuvant Therapy; Neovascularization, Pathologic; Sarcoma; Tetrahydroisoquinolines; TNF-Related Apoptosis-Inducing Ligand; Trabectedin | 2008 |
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2010 |
Systemic management strategies for metastatic soft tissue sarcoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dioxoles; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Lysine; Paclitaxel; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2011 |
Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease.
Topics: Antineoplastic Agents; Dioxoles; Doxorubicin; Evidence-Based Medicine; Humans; Ifosfamide; Indazoles; Pyrimidines; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
Trabectedin for the treatment of soft tissue sarcomas.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dioxoles; Disease Management; Humans; Ifosfamide; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
Systemic Treatment for Adults with Synovial Sarcoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Indazoles; Pyrimidines; Sarcoma, Synovial; Sulfonamides; Trabectedin | 2018 |
The Biology of Synovial Sarcoma: State-of-the-Art and Future Perspectives.
Topics: Anthracyclines; Antineoplastic Agents; Chemotherapy, Adjuvant; Epigenomics; Gene Expression Regulation, Neoplastic; Genomics; Humans; Ifosfamide; Indazoles; Molecular Targeted Therapy; Pyrimidines; Radiotherapy, Adjuvant; Sarcoma, Synovial; Soft Tissue Neoplasms; Sulfonamides; Surgical Procedures, Operative; Trabectedin | 2021 |
Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Topics: Doxorubicin; Humans; Ifosfamide; Liposarcoma; Sarcoma; Trabectedin | 2022 |
3 trial(s) available for ecteinascidin 743 and ifosfamide
| Article | Year |
|---|---|
Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Disease-Free Survival; Female; Humans; Ifosfamide; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; United Kingdom | 2007 |
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Australia; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Europe; Female; Humans; Ifosfamide; Infusions, Intravenous; Kaplan-Meier Estimate; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Staging; North America; Proportional Hazards Models; Risk Assessment; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Failure; Young Adult | 2009 |
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Administration Schedule; Fatigue; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nausea; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Translocation, Genetic; Treatment Outcome; Young Adult | 2014 |
14 other study(ies) available for ecteinascidin 743 and ifosfamide
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[A rare tumour with a distinctive histological appearance].
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arteriovenous Malformations; Bevacizumab; Biomarkers, Tumor; Combined Modality Therapy; Dactinomycin; Desmin; Diagnosis, Differential; Dioxoles; Doxorubicin; Humans; Ifosfamide; Leg; Lung Neoplasms; Male; Neoplasm Proteins; Prognosis; S100 Proteins; Sarcoma, Alveolar Soft Part; Soft Tissue Neoplasms; Staining and Labeling; Tetrahydroisoquinolines; Trabectedin; Vincristine | 2010 |
Mestastatic gastric cancer from malignant fibrous histiocytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dioxoles; Docetaxel; Epirubicin; Fatal Outcome; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Ifosfamide; Lung Neoplasms; Male; Soft Tissue Neoplasms; Spinal Neoplasms; Stomach Neoplasms; Taxoids; Tetrahydroisoquinolines; Thigh; Thoracic Vertebrae; Trabectedin | 2011 |
Role of palliative chemotherapy in advanced epithelioid sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Staging; Palliative Care; Prognosis; Prospective Studies; Retrospective Studies; Sarcoma; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2012 |
Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases.
Topics: Adult; Antineoplastic Agents; Axilla; Combined Modality Therapy; Dioxoles; Epirubicin; Fatal Outcome; Humans; Ifosfamide; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sarcoma, Synovial; Sorafenib; Tetrahydroisoquinolines; Trabectedin | 2014 |
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contraindications; Dacarbazine; Deoxycytidine; Dioxoles; Female; Femoral Neoplasms; Gemcitabine; Humans; Hysterectomy; Ifosfamide; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Thigh; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome; Uterine Neoplasms | 2015 |
Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Neoplasms; BRCA2 Protein; Dioxoles; Endometrial Neoplasms; Epirubicin; Female; Genes, BRCA2; Germ-Line Mutation; Humans; Ifosfamide; Liver Neoplasms; Middle Aged; Mutation, Missense; Sarcoma, Endometrial Stromal; Tetrahydroisoquinolines; Trabectedin | 2016 |
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cerebellar Neoplasms; Dacarbazine; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Furans; Humans; Ifosfamide; Ketones; Kidney Neoplasms; Male; Meningeal Neoplasms; Mice, SCID; Middle Aged; Pleural Neoplasms; Response Evaluation Criteria in Solid Tumors; Retroperitoneal Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Solitary Fibrous Tumors; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2017 |
Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Dioxoles; Female; Humans; Ifosfamide; Male; Middle Aged; Neutropenia; Retrospective Studies; Risk Factors; Sarcoma; Sarcopenia; Tetrahydroisoquinolines; Thinness; Trabectedin | 2018 |
Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Doxorubicin; Female; Humans; Ifosfamide; Liposarcoma; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Tertiary Care Centers; Trabectedin; Treatment Outcome; Young Adult | 2019 |
Sarcomas and old age: few options for such a large patient population.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Geriatric Assessment; Humans; Ifosfamide; Male; Prognosis; Sarcoma; Survival Rate; Trabectedin | 2019 |
Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Furans; Gemcitabine; Humans; Ifosfamide; Indazoles; Ketones; Liposarcoma; Middle Aged; Prognosis; Pyrimidines; Sulfonamides; Survival Rate; Trabectedin | 2019 |
Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Prognosis; Sarcoma; Survival Rate; Trabectedin | 2019 |